During the corresponding time, Biomerica Inc recorded a revenue increase by 16.96 % year on year, sequentially revenue fell by -11.25 %. While revenue at the Biomerica Inc 's corporate clients
Biomerica Inc's Comment on Sales, Marketing and Customers
The company operates in the diagnostic products market for gastrointestinal conditions and inflammatory diseases, including irritable bowel syndrome (IBS). Its product portfolio includes inFoods® IBS, a blood test designed to identify patient-specific foods to help reduce IBS symptoms, and hp+detect™, a diagnostic test for detecting Helicobacter pylori and monitoring treatment. The company focuses on chronic inflammatory illnesses and plans to expand the applications of inFoods® technology to diseases such as Functional Dyspepsia, Crohn’s Disease, Ulcerative Colitis, Gastroesophageal Reflux Disease (GERD), Migraine Headaches, Depression, and Osteoarthritis. Additionally, the company provides contract assay development and Contract Development and Manufacturing Organization (CDMO) services to third-party diagnostic and life science companies, offering development, optimization, testing support, technology transfer, and manufacturing services. Customers and markets mentioned in company filings include BioEurope GmbH and Biomerica.
Biomerica Inc., a leading global provider of advanced medical products, has recently unveiled a groundbreaking innovation that promises to significantly improve the lives of millions suffering from Irritable Bowel Syndrome (IBS). The company has launched an at-home sample collection feature for its highly acclaimed inFoods IBS system, aiming to simplify and revolutionize the patient experience.IBS, a common gastrointestinal disorder, affects approximately 10-15% of the global population. Its unpredictable nature and diverse set of symptoms often make it challenging to diagnose and manage effectively. Biomerica s inFoods IBS system, previously available only through clinics or medical professionals, utilizes ...
Biomerica, Inc. continues to push the boundaries of medical diagnostics with recent announcements that demonstrate their commitment to revolutionizing healthcare. The company, which specializes in advanced diagnostic and therapeutic products, has unveiled two significant milestones that have the potential to transform the landscape of medical testing.Firstly, Biomerica recently announced the initiation of a pilot program for its inFoods IBS product. Collaborating with a prominent 1,100-member physician group, this pilot launch is set to commence in June 2024. The inFoods IBS product represents a significant breakthrough in the field of irritable bowel syndrome (IBS) management, providing a non-invasive and r...
Biomerica Inc. has recently entered into an exclusive multi-year distribution agreement with a prominent healthcare conglomerate in the United Arab Emirates (UAE). The partnership aims to significantly enhance the accessibility and efficiency of colorectal cancer screening and breast examination technologies in the region. This strategic alliance has the potential to revolutionize healthcare practices and improve the early detection and treatment of these cancers.The partnership between Biomerica Inc. and the UAE healthcare conglomerate indicates a shared commitment to advancing medical screening technologies and improving patient outcomes. Colorectal cancer and breast cancer are major health concerns global...
Biomerica s Hp Detect ELISA Test Receives FDA Clearance, Paving the Way for Improved Detection of H. pylori Bacteria IRVINE, Calif., Dec. 18, 2023 - Biomerica, Inc. (Nasdaq: BMRA), a leading global provider of advanced medical diagnostic products, has achieved a major milestone with its recently granted U.S. Food and Drug Administration (FDA) 510(k) clearance for its Hp Detect Stool Antigen ELISA test. This innovative product is designed to detect the presence of the Helicobacter pylori (H. pylori) bacteria, a prevalent infection affecting approximately 35% of the U.S. population. H. pylori infection is a significant public health concern, impacting half of the world s population. The bacteria, ofte...
Biomerica Inc’s Comment on Sales, Marketing and Customers
The company operates in the diagnostic products market for gastrointestinal conditions and inflammatory diseases, including irritable bowel syndrome (IBS). Its product portfolio includes inFoods® IBS, a blood test designed to identify patient-specific foods to help reduce IBS symptoms, and hp+detect™, a diagnostic test for detecting Helicobacter pylori and monitoring treatment. The company focuses on chronic inflammatory illnesses and plans to expand the applications of inFoods® technology to diseases such as Functional Dyspepsia, Crohn’s Disease, Ulcerative Colitis, Gastroesophageal Reflux Disease (GERD), Migraine Headaches, Depression, and Osteoarthritis. Additionally, the company provides contract assay development and Contract Development and Manufacturing Organization (CDMO) services to third-party diagnostic and life science companies, offering development, optimization, testing support, technology transfer, and manufacturing services. Customers and markets mentioned in company filings include BioEurope GmbH and Biomerica.
Sources:
Biomerica Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Biomerica Inc’s corporate clients.
For your research, we’ve provided 9 tables on Biomerica Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
127.51 %